Quick Answer
CRISPR Therapeutics AG reported Net Income of -$581.60 million for fiscal year 2025.
CRISPR Therapeutics AG Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$581.60M | -58.8% |
| 2024 | -$366.25M | -138.4% |
| 2023 | -$153.61M | +76.4% |
| 2022 | -$650.17M | -272.2% |
| 2021 | $377.66M | +208.3% |
| 2020 | -$348.87M | -621.8% |
| 2019 | $66.86M | +140.5% |
| 2018 | -$164.98M | -141.4% |
| 2017 | -$68.36M | -194.9% |
| 2016 | -$23.18M | +9.1% |
| 2015 | -$25.50M | -263.9% |
| 2014 | -$7.01M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$106.44M | -23.9% | +49.0% |
| June 30, 2025 | -$208.55M | -65.0% | -53.3% |
| March 31, 2025 | -$136.00M | -16.6% | -58.2% |
| September 30, 2024 | -$85.94M | +23.4% | +32.0% |
| June 30, 2024 | -$126.41M | -62.6% | -8.4% |
| March 31, 2024 | -$116.59M | -119.7% | -4.0% |
| September 30, 2023 | -$112.15M | +35.7% | -44.3% |
| June 30, 2023 | -$77.74M | +58.2% | -46.5% |
- CRISPR Therapeutics AG showed a decrease of -58.8% in Net Income compared to the prior fiscal year.
- Over the 2014–2025 period, CRISPR Therapeutics AG’s net income has declined by 8197.9% (from -$7.01 million to -$581.60 million).
- The most recent figure is from CRISPR Therapeutics AG’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: